

# Overview of Phase III program for oral rolapitant



LEERINK SWANN

- 1 Moderately Emetogenic Chemotherapy (MEC) study
  - 1,350 patients
  - Day 1: Placebo or rolapitant (200mg) + granisetron + dexamethasone
  - Days 2-3: granisetron
  - Primary endpoint: no emetic episodes and no rescue medication (time 24-120 hours). Powered for ~10% delta in the drug vs. placebo group.
  - Secondary endpoints: acute phase response (time 0-24 hours), overall response rate (time 0-120 hours), and safety and tolerability
- The Phase 3 development program will report out in the 2H: 13